A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

ClinicalTrials.gov ID: NCT04152382

Public ClinicalTrials.gov record NCT04152382. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant. As part of protocol addendum, this study is additionally evaluating the safety and tolerability of LY3509754 in participants with psoriasis. Blood tests will be done to check how much LY3509754 is in the bloodstream and how long the body takes to get rid of it. The addendum will last up to 12 weeks for each participant.

Study identification

NCT ID: NCT04152382
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Psoriasis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 19, 2019
Primary completion: Feb 8, 2022
Completion: Feb 8, 2022
Last update posted: Mar 14, 2022

2019 – 2022

United States locations

U.S. sites: 10
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
Dermatology Associates - Los Angeles	Los Angeles	California	90045	—
Miami Dermatology and Laser Research	Miami	Florida	33173	—
Advanced Pharma Clinical Research	Miami	Florida	33175	—
ForCare Clinical Research	Tampa	Florida	33613-1244	—
Avita Clinical Research	Tampa	Florida	33613	—
Meridian Clinical Research	Baton Rouge	Louisiana	70808	—
DermDox Centers for Dermatology	Hazleton	Pennsylvania	18201	—
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15213	—
Progressive Clinical Research	San Antonio	Texas	78213	—
Texas Dermatology and Laser Specialists	San Antonio	Texas	78218	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04152382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 14, 2022 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04152382 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →